

# Financial Tear Sheet

## Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

## Stock Information

### FCSC (Common Stock)

<b>Exchange</b>	NASDAQ CM (US Dollar)
<b>Price</b>	<b>\$3.44</b>
<b>Change (%)</b>	<b>▼ 0.23 (6.27%)</b>
<b>Volume</b>	74,494
<b>52 Week Low</b>	\$1.57
<b>Market Cap</b>	\$50,627,051
<b>Rolling EPS</b>	-1.95
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	14,717,166

Data as of 09/22/17 4:00 p.m. ET



## Recent Headlines & Events

09/05/17 - 8:01 a.m.  
Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes' 2017 RARE Patient Advocacy Summit

08/09/17 - 8:01 a.m.  
Fibrocell Reports Second Quarter 2017 Financial

Date	Title
10/04/17 3:00 p.m. PT	<b>Fibrocell at Alliance for Regenerative Medicine Cell &amp; Gene Meeting on the Mesa</b> <b>Location</b> La Jolla, CA

## Results and Recent Highlights

08/03/17 - 8:00 a.m.

Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference

### SEC Filings

Filing Date	Form
08/09/17	10-Q
08/09/17	8-K
06/27/17	8-K
06/26/17	4

### Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

### Ownership Summary

#### Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	40	32.09	54.5	8,021,297
Mutual Fund	16	3.69	8.3	1,215,241
Director and Officer	1	.25	0.7	105,600

\*Insider values reflect direct beneficial ownership.

#### Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	5,540,140	37.6	0	06/30/17
Fidelity Management & Research Company	850,214	5.8	-18,598	06/30/17
MSD Partners, L.P.	692,960	4.7	0	06/30/17
The Vanguard Group, Inc.	346,576	2.4	-47,690	06/30/17
Renaissance Technologies LLC	108,264	0.7	21,400	06/30/17
Creative Planning, Inc.	61,090	0.4	48,755	06/30/17
Geode Capital Management, L.L.C.	58,710	0.4	-1,717	06/30/17
Parametric Portfolio Associates LLC	48,259	0.3	35,000	06/30/17
BlackRock Institutional Trust Company, N.A.	41,128	0.3	-25,683	06/30/17
California Public Employees' Retirement System	36,333	0.3	0	06/30/17

Data provided by Nasdaq. Minimum 15 minutes delayed.